Filing Flows › Integra Lifesciences Holdings (IART) › Q2 2026 › vs Q1 2026
Integra Lifesciences Holdings (IART) Q2 2026 vs Q1 2026 (quarter over quarter)
Integra Lifesciences Holdings's revenue rose $26.8M (+7%) from $392M in Q1 2026 to $419M in Q2 2026. The biggest changes: Specialty Surgery +$26.1M (+9%); Tissue Reconstruction +$709K (+0.7%). Operating margin 4.6% against 2.9% (+1.7 pts).
Integra Lifesciences Holdings, Q2 2026: revenue $419M (+0.8% year over year), operating margin 4.6%, net earnings $4.5M, operating cash flow $22.8M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 4.6% | 2.9% | +1.7 pts |
| Net margin | 1.1% | -1.2% | +2.2 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Specialty Surgery | $309M | $283M | $26.1M | +9% |
| Tissue Reconstruction | $109M | $109M | $709K | +0.7% |
| Revenue | $419M | $392M | $26.8M | +7% |
| Operating profit | $19.3M | $11.5M | $7.8M | +68% |
| Costs & expenses | $399M | $380M | $19.0M | +5% |
| Pre-tax earnings | $4.7M | −$2.4M | $7.2M | — |
| Other expense, net | $14.5M | $13.9M | $662K | +5% |
| Cost of revenue | $199M | $175M | $24.1M | +14% |
| Research & development | $24.3M | $23.5M | $752K | +3% |
| SG&A | $172M | $178M | −$5.8M | -3% |
| Other operating costs | $3.8M | $3.8M | −$6K | -0.2% |
| Net earnings | $4.5M | −$4.6M | $9.1M | — |
| Income tax | $262K | $2.2M | −$1.9M | -88% |
| Share-based compensation | $5.8M | $5.2M | $679K | +13% |
| Working capital & other | $12.5M | $9.3M | $3.2M | +35% |
| Operating cash flow | $22.8M | $9.8M | $13.0M | +133% |
Questions
How much did Integra Lifesciences Holdings's revenue grow quarter over quarter in Q2 2026?
Integra Lifesciences Holdings's revenue rose $26.8M (+7%) from $392M in Q1 2026 to $419M in Q2 2026.
What drove Integra Lifesciences Holdings's revenue change in Q2 2026?
Specialty Surgery +$26.1M (+9%); Tissue Reconstruction +$709K (+0.7%).